mGluR5-antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA model of autism

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Mehta, Mili V ^a   Gandal, Michael J ^a   Siegel, Steven J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; METABOTROPIC RECEPTOR 5; VALPROIC ACID; 6 METHYL 2 (PHENYLETHYNYL)PYRIDINE; 6-METHYL-2-(PHENYLETHYNYL)PYRIDINE; ANXIOLYTIC AGENT; METABOTROPIC RECEPTOR; PYRIDINE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTISM; COMPULSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; LOCOMOTION; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; STEREOTYPY; SYMPTOM; TRANQUILIZING ACTIVITY; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GROOMING; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PREGNANCY;

MUS;

ANIMALS; ANTI-ANXIETY AGENTS; AUTISTIC DISORDER; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; FEMALE; GROOMING; MICE; MOTOR ACTIVITY; PREGNANCY; PYRIDINES; RECEPTORS, METABOTROPIC GLUTAMATE; STEREOTYPED BEHAVIOR; VALPROIC ACID;

EID: 80053929841     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026077     Document Type: Article

References (49)

1. Brugha TS, McManus S, Bankart J, Scott F, Purdon S, et al. (2011) Epidemiology of autism spectrum disorders in adults in the community in England. Arch Gen Psychiatry 68: 459-465.
2. Kim YS, Leventhal BL, Koh YJ, Fombonne E, Laska E, et al. (2011) Prevalence of Autism Spectrum Disorders in a Total Population Sample. Am J Psychiatry.
3. Levy SE, Mandell DS, Schultz RT, (2009) Autism. Lancet 374: 1627-1638.
4. Richler J, Bishop SL, Kleinke JR, Lord C, (2007) Restricted and repetitive behaviors in young children with autism spectrum disorders. J Autism Dev Disord 37: 73-85.
5. King BH, Hollander E, Sikich L, McCracken JT, Scahill L, et al. (2009) Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 66: 583-590.
6. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, et al. (2005) Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162: 1142-1148.
7. Scahill L, Koenig K, Carroll DH, Pachler M, (2007) Risperidone approved for the treatment of serious behavioral problems in children with autism. J Child Adolesc Psychiatr Nurs 20: 188-190.
8. Adetunji B, Mathews M, Osinowo T, Williams A, (2006) Risperidone for the core symptom domains of autism. Am J Psychiatry 163: 551; author reply 551-552.
9. Jesner OS, Aref-Adib M, Coren E, (2007) Risperidone for autism spectrum disorder. Cochrane Database Syst Rev.
10. Geschwind DH, (2009) Advances in autism. Annu Rev Med 60: 367-380.
11. West L, Waldrop J, Brunssen S, (2009) Pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 23: 75-89.
12. McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, et al. (2011) A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 127: e1312-1321.
13. Rasalam AD, Hailey H, Williams JH, Moore SJ, Turnpenny PD, et al. (2005) Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol 47: 551-555.
14. Bromley RL, Mawer G, Clayton-Smith J, Baker GA, Liverpool, et al. (2008) Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 71: 1923-1924.
15. Gandal MJ, Edgar JC, Ehrlichman RS, Mehta M, Roberts TP, et al. (2010) Validating gamma oscillations and delayed auditory responses as translational biomarkers of autism. Biol Psychiatry 68: 1100-1106.
16. Schneider T, Przewlocki R, (2005) Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 30: 80-89.
17. Rubenstein JL, Merzenich MM, (2003) Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav 2: 255-267.
18. Gogolla N, Leblanc JJ, Quast KB, Sudhof T, Fagiolini M, et al. (2009) Common circuit defect of excitatory-inhibitory balance in mouse models of autism. J Neurodev Disord 1: 172-181.
19. Carlson GC, (2011) Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders. Pharmacol Biochem Behav.
20. Blundell J, Blaiss CA, Etherton MR, Espinosa F, Tabuchi K, et al. (2010) Neuroligin-1 deletion results in impaired spatial memory and increased repetitive behavior. J Neurosci 30: 2115-2129.
21. Silverman JL, Tolu SS, Barkan CL, Crawley JN, (2010) Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology 35: 976-989.
22. Anderson JJ, Bradbury MJ, Giracello DR, Chapman DF, Holtz G, et al. (2003) In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine). Eur J Pharmacol 473: 35-40.
23. Peca J, Feliciano C, Ting JT, Wang W, Wells MF, et al. (2011) Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 472: 437-442.
24. Silverman JL, Yang M, Lord C, Crawley JN, (2010) Behavioural phenotyping assays for mouse models of autism. Nat Rev Neurosci 11: 490-502.
25. Thomas A, Burant A, Bui N, Graham D, Yuva-Paylor LA, et al. (2009) Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology 204: 361-373.
26. Markram K, Rinaldi T, La Mendola D, Sandi C, Markram H, (2008) Abnormal fear conditioning and amygdala processing in an animal model of autism. Neuropsychopharmacology 33: 901-912.
27. de Vrij FM, Levenga J, van der Linde HC, Koekkoek SK, De Zeeuw CI, et al. (2008) Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 31: 127-132.
28. McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, et al. (2005) Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 45: 753-764.
29. Montana MC, Cavallone LF, Stubbert KK, Stefanescu AD, Kharasch ED, et al. (2009) The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine. J Pharmacol Exp Ther 330: 834-843.
30. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP, (2005) Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49: 1053-1066.
31. Guclu B, Tanidir C, Mukaddes NM, Unal F, (2007) Tactile sensitivity of normal and autistic children. Somatosensory & motor research 24: 21-33.
32. Bangash MA, Park JM, Melnikova T, Wang D, Jeon SK, et al. (2011) Enhanced Polyubiquitination of Shank3 and NMDA Receptor in a Mouse Model of Autism. Cell.
33. Rinaldi T, Kulangara K, Antoniello K, Markram H, (2007) Elevated NMDA receptor levels and enhanced postsynaptic long-term potentiation induced by prenatal exposure to valproic acid. Proc Natl Acad Sci U S A 104: 13501-13506.
34. Markram H, Rinaldi T, Markram K, (2007) The intense world syndrome-an alternative hypothesis for autism. Front Neurosci 1: 77-96.
35. Homayoun H, Moghaddam B, (2010) Group 5 metabotropic glutamate receptors: role in modulating cortical activity and relevance to cognition. Eur J Pharmacol 639: 33-39.
36. Pittenger C, Krystal JH, Coric V, (2006) Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 3: 69-81.
37. Comer JS, Kendall PC, Franklin ME, Hudson JL, Pimentel SS, (2004) Obsessing/worrying about the overlap between obsessive-compulsive disorder and generalized anxiety disorder in youth. Clin Psychol Rev 24: 663-683.
38. Crawley JN, (2004) Designing mouse behavioral tasks relevant to autistic-like behaviors. Ment Retard Dev Disabil Res Rev 10: 248-258.
39. Crawley JN, (2007) Mouse behavioral assays relevant to the symptoms of autism. Brain Pathol 17: 448-459.
40. Moy SS, Nadler JJ, Poe MD, Nonneman RJ, Young NB, et al. (2008) Development of a mouse test for repetitive, restricted behaviors: relevance to autism. Behav Brain Res 188: 178-194.
41. Pearson BL, Pobbe RL, Defensor EB, Oasay L, Bolivar VJ, et al. (2011) Motor and cognitive stereotypies in the BTBR T+tf/J mouse model of autism. Genes Brain Behav 10: 228-235.
42. Lewis MH, Tanimura Y, Lee LW, Bodfish JW, (2007) Animal models of restricted repetitive behavior in autism. Behav Brain Res 176: 66-74.
43. Kalueff AV, Tuohimaa P, (2005) Contrasting grooming phenotypes in three mouse strains markedly different in anxiety and activity (129S1, BALB/c and NMRI). Behav Brain Res 160: 1-10.
44. Broekkamp CL, Rijk HW, Joly-Gelouin D, Lloyd KL, (1986) Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur J Pharmacol 126: 223-229.
45. Greer JM, Capecchi MR, (2002) Hoxb8 is required for normal grooming behavior in mice. Neuron 33: 23-34.
46. Brodkin J, Busse C, Sukoff SJ, Varney MA, (2002) Anxiolytic-like activity of the mGluR5 antagonist MPEP: a comparison with diazepam and buspirone. Pharmacol Biochem Behav 73: 359-366.
47. Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, et al. (2000) Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 295: 1267-1275.
48. Busse CS, Brodkin J, Tattersall D, Anderson JJ, Warren N, et al. (2004) The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 29: 1971-1979.
49. Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, et al. (2001) Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 132: 1423-1430.